FOLH1 and mismatch repair cancer syndrome 1: Previously approved regimens included taxane-based chemotherapy (docetaxel and cabazitaxel), ARPIs (abiraterone, apalutamide, and enzalutamide), Lutetium-177-PSMA-617 (in patients with high PSMA expression), Radium-223 (in patients with bone metastasis and minimal symptoms), and pembrolizumab (in patients with high microsatellite instability or mismatch repair deficiency) [3], thus stressing the need to refine patient counseling and treatment sequence selection in the clinic.